Analysts: Sarepta’s Competitor Eliminated and 3 Other Research Notes to Browse
Sarepta (NASDAQ:SRPT): RW Baird says that the elimination of Prosensa (NASDAQ:RNA) as a potential competitor more than offsets any increase in risk for Sarepta following the failed Phase 3 trial for drisapersen. Baird said it has increased bullishness on Sarepta following today’s news and keeps an Outperform rating on the stock.
Nielsen (NYSE:NLSN): Bernstein downgraded Nielsen to Market Perform from Outperform due to expected normalized market returns and the likelihood of a secondary offering post-deal announcement. The shares’ price target is $40.
TASER (NASDAQ:TASR): Craig-Hallum believes that the growth in the number of video cameras worn by police officers is set to accelerate significantly. The firm notes that TASER is the leading provider of this solution, and it thinks that the company has a “massive opportunity” in this area. The firm raised its price target on the shares to $20 from $11, and it keeps a Buy rating on the stock.
Matador (NYSE:MTDR): Stifel increased its target on Matador to $20 from $15 as the firm now has a more positive view of the company’s Permian Basin properties. The firm thinks that the company is poised to exceed expectations in the second half of 2013, and it reiterates a Buy rating on the stock.